Table 1.
Total (n = 116)† | Underlying SLE (n = 61) | Underlying AOSD (n = 31) | P‡ | |
---|---|---|---|---|
Age, mean ± SD (range) years | 41.6 ± 18.7 (16–86) | 34.4 ± 14.2 | 43.4 ± 17.4 | 0.014 |
Male:female ratio | 1:3 | 1:4.1 | 1:4.2 | |
Physical findings | ||||
Fever, no./total no. (%)§ | 99/114 (86.8) | 56/60 (93.3) | 30/31 (96.8) | NS |
Lymphadenopathy, no./total no. (%) | 32/78 (41) | 16/40 (40) | 13/24 (54.2) | NS |
Hepatomegaly, no./total no. (%) | 28/67 (41.8) | 12/29 (41.3) | 10/20 (50) | NS |
Splenomegaly, no./total no. (%) | 40/88 (45.5) | 15/43 (34.9) | 16/25 (64) | NS |
Laboratory findings | ||||
WBC count, mean ± SD (range) ×109/liter | 4.1 ± 6.08 (0.1–41.1) | 2.2 ± 1.2 | 6.8 ± 6.6 | 0.002 |
Hgb, mean ± SD (range) gm/dl | 8.9 ± 2 (4.8–14.1) | 8.7 ± 1.8 | 9.6 ± 1.9 | NS |
Platelet count, mean ± SD (range) ×109/liter | 98.1 ± 96.8 (2–560) | 81.9 ± 52.2 | 141.9 ± 142 | NS |
Coagulopathy, no./total no. (%)¶ | 40/79 (50.6) | 24/35 (68.6) | 12/27 (44.4) | NS |
AST, mean ± SD (range) IU/liter | 264.2 ± 548 (9–3,420) | 211.3 ± 341 | 423.4 ± 757.9 | NS |
ALT, mean ± SD (range) IU/liter | 183.6 ± 351 (6–2,126) | 96.1 ± 117 | 315.9 ± 402 | 0.029 |
LDH, mean ± SD (range) IU/liter | 1,251 ± 1,592 (115–10,586) | 1,012 ± 974 | 1,923.1 ± 1,721 | NS |
CRP, mean ± SD (range) mg/dl | 7.7 ± 10.2 (0.2–39.3) | 2.8 ± 4.0 | 14.9 ± 12.6 | 0.00002 |
Ferritin, mean ± SD (range) μg/liter | 15,334.1 ± 35,181 (16–210,000) | 5,849.5 ± 10,472 | 40,136.4 ± 64,069.7 | 0.003 |
NS = not significant; WBC = white blood cell; Hgb = hemoglobin; AST = aspartate aminotransferase; ALT = alanine aminotransferase; LDH = lactate dehydrogenase; CRP = C-reactive protein.
Includes the 61 patients with underlying systemic lupus erythematosus (SLE), the 31 with underlying adult-onset Still's disease (AOSD), and the 24 with other autoimmune diseases underlying autoimmune-associated hemophagocytic syndrome (AAHS).
Underlying SLE versus underlying AOSD.
Body temperature ≥37.5°C.
Hypofibrinogenemia, increased fibrinogen degradation products, or prolonged prothrombin time or activated partial thromboplastin time.